{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T23:34:15Z","timestamp":1721345655356},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.clinthera.2010.07.013","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T08:59:22Z","timestamp":1280998762000},"page":"1372-1386","source":"Crossref","is-referenced-by-count":5,"title":["An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct00709553","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Helen K.","family":"Tomkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John V.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wollseifen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart D.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.07.013_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.clinthera.2010.07.013_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/003335490411900211","article-title":"Prostate cancer incidence and mortality rates and trends in the United States and Canada","volume":"119","author":"McDavid","year":"2004","journal-title":"Public Health Rep."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.07.013_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1464-410X.2005.05946.x","article-title":"Therapeutic options in androgen-independent prostate cancer: Building on docetaxel","volume":"96","author":"Petrylak","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2010.07.013_bib4_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ucl.2005.12.010","article-title":"Mechanisms leading to the development of hormone-resistant prostate cancer","volume":"33","author":"Kasper","year":"2006","journal-title":"Urol Clin North Am."},{"key":"10.1016\/j.clinthera.2010.07.013_bib4_2","doi-asserted-by":"crossref","first-page":"vii","DOI":"10.1016\/j.ucl.2005.12.010","article-title":"Mechanisms leading to the development of hormone-resistant prostate cancer","volume":"33","author":"Kasper","year":"2006","journal-title":"Urol Clin North Am."},{"key":"10.1016\/j.clinthera.2010.07.013_bib5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.07.013_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.07.013_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/1-4020-7847-1_14","article-title":"Targeting endothelin axis in cancer","volume":"119","author":"Bagnato","year":"2004","journal-title":"Cancer Treat Res."},{"key":"10.1016\/j.clinthera.2010.07.013_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc990","article-title":"The endothelin axis: Emerging role in cancer","volume":"3","author":"Nelson","year":"2003","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.clinthera.2010.07.013_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1593\/neo.04787","article-title":"Endothelin-1 inhibits apoptosis in prostate cancer","volume":"7","author":"Nelson","year":"2005","journal-title":"Neoplasia."},{"key":"10.1016\/j.clinthera.2010.07.013_bib10","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.bjc.6602676","article-title":"Specific inhibition of the endothelin A receptor with ZD4054: Clinical and preclinical evidence","volume":"92","author":"Morris","year":"2005","journal-title":"Br J Cancer."},{"key":"10.1016\/j.clinthera.2010.07.013_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1043-2760(02)00010-3","article-title":"Emerging role of endothelin-1 in tumor angiogenesis","volume":"14","author":"Bagnato","year":"2003","journal-title":"Trends Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2010.07.013_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000101307","article-title":"Epithelialmesenchymal transition in ovarian cancer progression: A crucial role for the endothelin axis","volume":"185","author":"Bagnato","year":"2007","journal-title":"Cells Tissues Organs."},{"key":"10.1016\/j.clinthera.2010.07.013_bib13","first-page":"8340","article-title":"Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells","volume":"61","author":"Rosan\u00f2","year":"2001","journal-title":"Cancer Res."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.07.013_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11129","article-title":"Role of endothelin-1 in osteoblastic bone metastases","volume":"97","author":"Guise","year":"2003","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2010.07.013_bib15","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1074\/jbc.273.20.12584","article-title":"Endothelin-induced apoptosis of A375 human melanoma cells","volume":"273","author":"Okazawa","year":"1998","journal-title":"J Biol Chem."},{"key":"10.1016\/j.clinthera.2010.07.013_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.20252","article-title":"Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma","volume":"65","author":"Godara","year":"2005","journal-title":"Prostate."},{"key":"10.1016\/j.clinthera.2010.07.013_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0022-5347(05)66597-4","article-title":"Expression of endothelin receptor a associated with prostate cancer progression","volume":"165","author":"Gohji","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2010.07.013_bib18","first-page":"1132","article-title":"ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation","volume":"231","author":"Rosan\u00f2","year":"2006","journal-title":"Exp Biol Med (Maywood)."},{"key":"10.1016\/j.clinthera.2010.07.013_bib19","article-title":"ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole","author":"Smollich","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2010.07.013_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CAD.0b013e328320791c","article-title":"Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054","volume":"20","author":"Growcott","year":"2009","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.clinthera.2010.07.013_bib21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin\u2014A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2010.07.013_bib22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/00498250902810944","article-title":"In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers","volume":"39","author":"Swaisland","year":"2009","journal-title":"Xenobiotica."},{"key":"10.1016\/j.clinthera.2010.07.013_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: Regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.1016\/j.clinthera.2010.07.013_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.07.013_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-540-74806-9_16","article-title":"Midazolam and other benzodiazepines","author":"Olkkola","year":"2008","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.clinthera.2010.07.013_bib26","series-title":"Cytochrome P450: Structure, Mechanism and Biochemistry","year":"1995"},{"key":"10.1016\/j.clinthera.2010.07.013_bib29","article-title":"WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects","year":"1964","journal-title":"Adopted by the 18th WMA General Assembly, Helsinki, Finland"},{"key":"10.1016\/j.clinthera.2010.07.013_bib31","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1016\/j.clinthera.2010.07.013_bib32","series-title":"Cross-over Trials in Clinical Research","author":"Senn","year":"2002"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.07.013_bib33","first-page":"771","article-title":"Relative bioavailability of zibotentan (ZD4054) immediate release tablets compared with a reference oral formulation: A Phase I study in healthy male volunteers","volume":"11","author":"Tomkinson","year":"2009","journal-title":"AAPSJ."},{"key":"10.1016\/j.clinthera.2010.07.013_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0736-4679(97)00022-X","article-title":"Midazolam: A review of therapeutic uses and toxicity","volume":"15","author":"Nordt","year":"1997","journal-title":"J Emerg Med."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T10:00:48Z","timestamp":1559383248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810002407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0149291810002407"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.07.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}